Universal Ibogaine Inc. is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that protocol globally through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.
Stock Performance
Universal Ibogaine Inc. News 11 articles
- Democratic Presidential Candidate Wants Psychedelics Covered by Healthcare
- Psychedelics and Grief: Processing Trauma & Rewiring the Brain
- PsychedelicNewsBreaks – Universal Ibogaine Inc. Recaps 2022, Eyes 2023 as ‘Pivotal Year’
- Universal Ibogaine Announces Formation of Advisory Board
- Universal Ibogaine Announces Results of Annual General Meeting
- Universal Ibogaine Undertaking Offering of Convertible Debt Securities and Common Shares
- Universal Ibogaine Featured in Psychedelics Tonight Documentary Series
- Universal Ibogaine Announces Kelburn Reopening Date
- Universal Ibogaine Provides Update on Kelburn Recovery Center
- Universal Ibogaine Provides Update on Kelburn Recovery Center
- Universal Ibogaine Retains Westmount Park Investments for Corporate Financial Advisory Services